Quince Therapeutics Inc (NAS:QNCX)

$ 0.9199 0.0119 (1.31%) Market Cap: 39.75 Mil Enterprise Value: -14.49 Mil PE Ratio: 0 PB Ratio: 0.53 GF Score: 39/100

Quince Therapeutics Inc Annual Shareholders Meeting Transcript
May 24, 2023
Cortexyme Inc To Discuss The GAIN Trial Top-Line Results Call Transcript
Oct 26, 2021
Cortexyme Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 13, 2021
Cortexyme Inc at Canaccord Genuity Growth Conference (Virtual) Transcript
Aug 11, 2021
Cortexyme Inc Corporate To Discuss Innovation in Alzheimers Disease -- Getting to the Root Cause of Neurodegeneration Webinar Transcript
Jul 30, 2021
Cortexyme Inc Corporate To Discuss Innovation in Periodontal Disease -- A Major Unmet Medical Need Webinar Transcript
Jul 23, 2021
Cortexyme Inc at JMP Securities Life Sciences Virtual Conference Transcript
Jun 16, 2021
Cortexyme Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 02, 2021
Cortexyme Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 11, 2021
Cortexyme Inc at Stifel CNS Day - Fireside Chat Transcript
Apr 01, 2021
Cortexyme Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 16, 2021
Cortexyme Inc GAIN Trial Interim Analysis Update Call Transcript
Dec 04, 2020

Cortexyme Inc To Discuss The GAIN Trial Top-Line Results Call Transcript

Oct 26, 2021 / 08:30PM GMT

Release Date Price: $57.68 (-2.68%)

Transcript 10-Q

Operator

Greetings. Welcome to Cortexyme Conference Call. (Operator Instructions) Please note, this conference is being recorded.

I will now turn the conference over to Stacy Roughan. Thank you. You may begin.

Stacy Roughan

Cortexyme, Inc. - VP of Corporate Communications & IR

Welcome, and thank you for joining us to discuss top line results from our GAIN trial. With us from management are Casey Lynch, our Chief Executive Officer, Co-Founder and Chair; Mike Detke, Chief Medical Officer; and Chris Lowe, our Chief Operating Officer and Chief Financial Officer. You can find today's news release, along with the presentation that management will refer to in their prepared remarks, on our Investor Relations website at ir.cortexyme.com.

During the course of our remarks today, we will be making forward-looking statements, including statements relating to the outcome and results of the GAIN trial, the timing of related announcements and updates, the potential of atuzaginstat to treat Alzheimer's disease and opportunities to treat other chronic health

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.